The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global local anesthesia drugs market size reached US$ 2.77 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 3.62 Billion by 2027, exhibiting a growth rate (CAGR) of 4.30% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Local anesthesia drugs are chemical compounds producing anesthesia by inhibiting the excitation of nerve endings or blocking conduction in peripheral nerves. They are generally available as topical creams or administered via injections or sprays during minor surgeries, biopsies, dental care, labor and delivery, and obstetrical procedures. They help treat painful conditions, such as mouth ulcers and sore throat, and relieve itching caused by cuts, minor burns, sunburns, scratches, insect bites, and poison ivy. They also assist in rapid and effective pain relief during gastritis, esophagitis, hiatus hernia, and heartburn of peptic ulcer.
The rising prevalence of cardiovascular, respiratory, and other chronic diseases that need several procedures, such as cochlear implantation, laparoscopic colectomy, laparoscopic hysterectomy, secondary hip replacement, and knee replacement, represents one of the key factors bolstering the market growth. Furthermore, the growing geriatric population undergoing surgical interventions that require post-operative pain relief is catalyzing the demand for local anesthesia drugs across the globe. Moreover, the increasing number of dental surgeries, in confluence with the introduction of novel and effective medicines like articaine, levobupivacaine and ropivacaine, is propelling the market growth. Apart from this, due to the increasing consciousness about physical appearance among individuals, there is a rise in the demand for minimally invasive (MI) cosmetic surgical procedures, such as botulinum toxin and facial filler injections, which is contributing to the market growth. In addition to this, expanding medical tourism activities, along with developments in the healthcare infrastructure, are creating a positive market outlook. Besides this, technological advancements, including computer-based local anesthetic delivery and vibrotactile devices, are anticipated to provide a positive thrust to the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global local anesthesia drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug type, mode of administration and distribution channel.
Breakup by Drug Type:
Breakup by Mode of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aspen Pharmacare Holdings Limited, B. Braun Melsungen AG, Baxter International Inc., Endo International plc, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Pacira Biosciences Inc., Pfizer Inc., Pierrel S.p.A. and Septodont.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug Type, Mode of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aspen Pharmacare Holdings Limited, B. Braun Melsungen AG, Baxter International Inc., Endo International plc, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Pacira Biosciences Inc., Pfizer Inc., Pierrel S.p.A. and Septodont.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at